Patents by Inventor Nicholas J. Agard

Nicholas J. Agard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED PHENYLALANINE AMMONIA LYASE POLYPEPTIDES
    Publication number: 20210222146
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Application
    Filed: April 1, 2021
    Publication date: July 22, 2021
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • ENGINEERED PHENYLALANINE AMMONIA LYASE POLYPEPTIDES
    Publication number: 20210222145
    Abstract: The present invention provides engineered phenylalanine ammonia lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia lyase (PAL) polypeptides. In some embodiments, the engineered PAL polypeptides are optimized to provide enhanced catalytic activity, as well as reduced sensitivity to proteolysis and increased tolerance to storage at elevated temperatures. In some embodiments, the engineered PAL polypeptides contain fewer phenylalanine residues than wild-type PAL polypeptides. The present invention also provides methods for the use of the compositions comprising the engineered PAL polypeptides for therapeutic and industrial purposes.
    Type: Application
    Filed: March 31, 2021
    Publication date: July 22, 2021
    Inventors: Chinping Chng, William Casey Hallows, Nicholas J. Agard, Oscar Alvizo, Nikki Dellas, Gjalt W. Huisman, John Joseph Nicols
  • Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
    Patent number: 11060072
    Abstract: The present application provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: July 13, 2021
    Assignee: Codexis, Inc.
    Inventors: Nicholas J. Agard, Oscar Alvizo, Melissa Ann Mayo, Stefanie Ng Minor, James Nicholas Riggins, Jeffrey C. Moore
  • Polynucleotides encoding engineered tyrosine ammonia lyase variants
    Patent number: 11015184
    Abstract: The present invention provides engineered tyrosine ammonia-lyase (TAL) polypeptides and compositions thereof. In some embodiments, the engineered TAL polypeptides have been optimized to provide enhanced catalytic activity while reducing sensitivity to proteolysis and increasing tolerance to acidic pH levels. The invention also provides methods for utilization of the compositions comprising the engineered TAL polypeptides for therapeutic and industrial purposes.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: May 25, 2021
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, David Elgart, Xiyun Zhang
  • Engineered phenylalanine ammonia lyase polypeptides
    Patent number: 10995329
    Abstract: The present invention provides engineered phenylalanine ammonia lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia lyase (PAL) polypeptides. In some embodiments, the engineered PAL polypeptides are optimized to provide enhanced catalytic activity, as well as reduced sensitivity to proteolysis and increased tolerance to storage at elevated temperatures. In some embodiments, the engineered PAL polypeptides contain fewer phenylalanine residues than wild-type PAL polypeptides. The present invention also provides methods for the use of the compositions comprising the engineered PAL polypeptides for therapeutic and industrial purposes.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: May 4, 2021
    Assignee: Codexis, Inc.
    Inventors: Chinping Chng, William Casey Hallows, Nicholas J. Agard, Oscar Alvizo, Nikki Dellas, Gjalt W. Huisman, John Joseph Nicols
  • Engineered phenylalanine ammonia lyase polypeptides
    Patent number: 10975367
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: April 13, 2021
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • Human alpha-galactosidase variants
    Patent number: 10973888
    Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: April 13, 2021
    Assignee: Codexis, Inc.
    Inventors: Nicholas J. Agard, Mathew G. Miller, Xiyun Zhang, Gjalt W. Huisman
  • Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
    Patent number: 10947572
    Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: March 16, 2021
    Assignee: Codexis, Inc.
    Inventors: Haibin Chen, Steven J. Collier, Jovana Nazor, Joly Sukumaran, Derek Smith, Jeffrey C. Moore, Gregory Hughes, Jacob Janey, Gjalt W. Huisman, Scott J. Novick, Nicholas J. Agard, Oscar Alvizo, Gregory A. Cope, Wan Lin Yeo, Stefanie Ng Minor
  • Engineered phenylalanine ammonia lyase polypeptides
    Patent number: 10941391
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: March 9, 2021
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS
    Publication number: 20210054422
    Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
    Type: Application
    Filed: November 6, 2020
    Publication date: February 25, 2021
    Inventors: Haibin Chen, Steven J. Collier, Jovana Nazor, Joly Sukumaran, Derek Smith, Jeffrey C. Moore, Gregory Hughes, Jacob Janey, Gjalt W. Huisman, Scott J. Novick, Nicholas J. Agard, Oscar Alvizo, Gregory A. Cope, Wan Lin Yeo, Stefanie Ng Minor
  • HUMAN ALPHA-GALACTOSIDASE VARIANTS
    Publication number: 20200405826
    Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH <4.5) and basic (pH >7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
    Type: Application
    Filed: August 5, 2020
    Publication date: December 31, 2020
    Inventors: Nicholas J. Agard, Mathew G. Miller, Xiyun Zhang, Gjalt W. Huisman
  • ENGINEERED PHENYLALANINE AMMONIA LYASE POLYPEPTIDES
    Publication number: 20200399627
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Application
    Filed: September 2, 2020
    Publication date: December 24, 2020
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • Engineered phenylalanine ammonia lyase polypeptides
    Patent number: 10870843
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: December 22, 2020
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS
    Publication number: 20200385768
    Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
    Type: Application
    Filed: August 25, 2020
    Publication date: December 10, 2020
    Inventors: Haibin Chen, Steven J. Collier, Jovana Nazor, Joly Sukumaran, Derek Smith, Jeffrey C. Moore, Gregory Hughes, Jacob Janey, Gjalt W. Huisman, Scott J. Novick, Nicholas J. Agard, Oscar Alvizo, Gregory A. Cope, Wan Lin Yeo, Stefanie Ng Minor
  • HUMAN ALPHA-GALACTOSIDASE VARIANTS
    Publication number: 20200360490
    Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
    Type: Application
    Filed: August 5, 2020
    Publication date: November 19, 2020
    Inventors: Nicholas J. Agard, Mathew G. Miller, Xiyun Zhang, Gjalt W. Huisman
  • HUMAN ALPHA-GALACTOSIDASE VARIANTS
    Publication number: 20200360489
    Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH <4.5) and basic (pH >7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
    Type: Application
    Filed: August 5, 2020
    Publication date: November 19, 2020
    Inventors: Nicholas J. Agard, Mathew G. Miller, Xiyun Zhang, Gjalt W. Huisman
  • KETOREDUCTASE POLYPEPTIDES FOR THE SYNTHESIS OF CHIRAL COMPOUNDS
    Publication number: 20200347365
    Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds.
    Type: Application
    Filed: May 14, 2020
    Publication date: November 5, 2020
    Inventors: Oscar Alvizo, Nicholas J. Agard, Xinkai Xie, David Entwistle, Birgit Kosjek
  • Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
    Patent number: 10787689
    Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: September 29, 2020
    Assignee: Codexis, Inc.
    Inventors: Haibin Chen, Steven J. Collier, Jovana Nazor, Joly Sukumaran, Derek Smith, Jeffrey C. Moore, Gregory Hughes, Jacob Janey, Gjalt W. Huisman, Scott J. Novick, Nicholas J. Agard, Oscar Alvizo, Gregory A. Cope, Wan Lin Yeo, Stefanie Ng Minor
  • ENGINEERED PHENYLALANINE AMMONIA LYASE POLYPEPTIDES
    Publication number: 20200231959
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Application
    Filed: March 26, 2020
    Publication date: July 23, 2020
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • Engineered phenylalanine ammonia lyase polypeptides
    Patent number: 10717974
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: July 21, 2020
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang